Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus

Ye Sang,Zhen Zhang,Fan Liu,Haitao Lu,Changxiao Yu,Huisheng Sun,Jinrong Long,Yiming Cao,Jierui Mai,Yiqi Miao,Xin Wang,Jiaxin Fang,Youchun Wang,Weijin Huang,Jing Yang,Shengqi Wang
DOI: https://doi.org/10.1038/s41392-023-01432-5
IF: 39.3
2023-04-29
Signal Transduction and Targeted Therapy
Abstract:Monkeypox has been declared a public health emergency by the World Health Organization. There is an urgent need for efficient and safe vaccines against the monkeypox virus (MPXV) in response to the rapidly spreading monkeypox epidemic. In the age of COVID-19, mRNA vaccines have been highly successful and emerged as platforms enabling rapid development and large-scale preparation. Here, we develop two MPXV quadrivalent mRNA vaccines, named mRNA-A-LNP and mRNA-B-LNP, based on two intracellular mature virus specific proteins (A29L and M1R) and two extracellular enveloped virus specific proteins (A35R and B6R). By administering mRNA-A-LNP and mRNA-B-LNP intramuscularly twice, mice induce MPXV specific IgG antibodies and potent vaccinia virus (VACV) specific neutralizing antibodies. Further, it elicits efficient MPXV specific Th-1 biased cellular immunity, as well as durable effector memory T and germinal center B cell responses in mice. In addition, two doses of mRNA-A-LNP and mRNA-B-LNP are protective against the VACV challenge in mice. And, the passive transfer of sera from mRNA-A-LNP and mRNA-B-LNP-immunized mice protects nude mice against the VACV challenge. Overall, our results demonstrate that mRNA-A-LNP and mRNA-B-LNP appear to be safe and effective vaccine candidates against monkeypox epidemics, as well as against outbreaks caused by other orthopoxviruses, including the smallpox virus.
biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to develop effective and safe vaccines against the monkeypox virus (MPXV). Specifically, the researchers developed two tetravalent mRNA vaccines (mRNA - A - LNP and mRNA - B - LNP), which are based on two intracellular mature virus - specific proteins (A29L and M1R) and two extracellular enveloped virus - specific proteins (A35R and B6R) of the monkeypox virus. Administered by two intramuscular injections, these vaccines induced monkeypox - virus - specific IgG antibodies and potent neutralizing antibodies against vaccinia virus (VACV) in mice. In addition, these vaccines also elicited effective Th1 - skewed cellular immune responses and generated long - lasting memory T - cell and germinal - center B - cell responses. The study also showed that these two vaccines can protect mice from vaccinia - virus challenge, which was further confirmed by passive transfer experiments. Overall, the research results indicate that mRNA - A - LNP and mRNA - B - LNP are safe and effective candidate vaccines against the monkeypox epidemic and epidemics caused by other orthopoxviruses (such as the smallpox virus).